Actively Recruiting
Tau PET/CT Imaging in Patients with Various Tau-Related Diseases
Led by Tianjin Medical University · Updated on 2025-02-11
500
Participants Needed
2
Research Sites
4 weeks
Total Duration
On this page
Sponsors
T
Tianjin Medical University
Lead Sponsor
T
Tianjin Medical University General Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are evaluating the potential usefulness of 18F-S16/T807 positron emission tomography/computed tomography (PET/CT) for detecting primary and metastatic lesions in patients with various Tau-related diseases. This observational study focuses on patients with suspected, newly diagnosed, or previously treated malignant tumors related to Tauopathies and neurodegenerative diseases. The goal is to assess the diagnostic value of this imaging technique in these conditions. Participants receive a single intravenous injection of 18F-S16/T807, followed by PET/CT or MRI imaging within a specified time frame. This imaging process is used either for initial assessment or to detect recurrence of lesions. The study measures include quantifying lesion uptake by the maximum standardized uptake value (SUVmax) and calculating diagnostic accuracy parameters such as sensitivity, specificity, positive predictive value, and negative predictive value. During the study, participants undergo the imaging procedure and provide informed consent. Researchers monitor and evaluate the standardized uptake value (SUV) within 30 days as the primary outcome, while diagnostic efficacy is assessed as a secondary outcome. The study includes adults aged 18 to 80 years and involves healthy volunteers as well. The total participation time includes the imaging and assessment period within one month.
CONDITIONS
Brief Title
Tau PET/CT in Various Tau-Related Disease Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patients aged 18 years or older
- Patients with suspected, newly diagnosed, or previously treated malignant tumors supported by MRI, CT, tumor markers, or pathology
- Patients scheduled for a Tau PET/CT scan
- Patients able to provide informed consent and assent according to ethics guidelines
You will not qualify if you...
- Patients with non-malignant lesions
- Pregnant patients
- Patients or their legal representatives unwilling or unable to provide written informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Within 30 days
Participants receive a single intravenous injection of 18F-S16/T807 and undergo PET/CT or MRI imaging to assess Tau-related disease.
1 visit (in-person)
Duration - Up to 30 days
Participants are observed for diagnostic efficacy and standardized uptake value outcomes up to 30 days after imaging.
Follow-up assessments as needed
Trial Site Locations
Total: 2 locations
1
The First Affiliated Hospital of University of Science and Technology of China
Hefei, Anhui, China, 230000
Actively Recruiting
2
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, China, 300052
Actively Recruiting
Research Team
Y
Ying Wang, MD
S
Shaobo Yao, PhD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here